273 related articles for article (PubMed ID: 36923535)
1. First
Starke L; Millward JM; Prinz C; Sherazi F; Waiczies H; Lippert C; Nazaré M; Paul F; Niendorf T; Waiczies S
Theranostics; 2023; 13(4):1217-1234. PubMed ID: 36923535
[TBL] [Abstract][Full Text] [Related]
2.
Prinz C; Starke L; Millward JM; Fillmer A; Delgado PR; Waiczies H; Pohlmann A; Rothe M; Nazaré M; Paul F; Niendorf T; Waiczies S
Theranostics; 2021; 11(6):2490-2504. PubMed ID: 33456555
[No Abstract] [Full Text] [Related]
3. Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Arnold DL; Piani-Meier D; Bar-Or A; Benedict RH; Cree BA; Giovannoni G; Gold R; Vermersch P; Arnould S; Dahlke F; Hach T; Ritter S; Karlsson G; Kappos L; Fox RJ;
Mult Scler; 2022 Sep; 28(10):1526-1540. PubMed ID: 35261318
[TBL] [Abstract][Full Text] [Related]
4. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Hua LH; Bar-Or A; Cohan SL; Lublin FD; Coyle PK; Cree BA; Meng X; Su W; Cox GM; Fox RJ
Mult Scler Relat Disord; 2023 Jul; 75():104766. PubMed ID: 37245350
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
Gajofatto A
Drug Des Devel Ther; 2017; 11():3153-3157. PubMed ID: 29138536
[TBL] [Abstract][Full Text] [Related]
6. Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5.
Behrangi N; Heinig L; Frintrop L; Santrau E; Kurth J; Krause B; Atanasova D; Clarner T; Fragoulis A; Joksch M; Rudolf H; Meuth SG; Joost S; Kipp M
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2204509119. PubMed ID: 36161894
[TBL] [Abstract][Full Text] [Related]
7. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
[TBL] [Abstract][Full Text] [Related]
8. Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA.
Ziemssen T; Hoffmann O; Klotz L; Schreiber H; Weber MS; Rauser B
JMIR Res Protoc; 2020 Jul; 9(7):e19598. PubMed ID: 32499214
[TBL] [Abstract][Full Text] [Related]
9. Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review.
Li Q; Jing LJ; Li Y; Jia Y
BMC Neurol; 2023 Jul; 23(1):286. PubMed ID: 37525104
[TBL] [Abstract][Full Text] [Related]
10. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
Gurrea-Rubio M; Wang Q; Mills EA; Wu Q; Pitt D; Tsou PS; Fox DA; Mao-Draayer Y
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473703
[TBL] [Abstract][Full Text] [Related]
11. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
[TBL] [Abstract][Full Text] [Related]
12. Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
Hussain R; O'Leary S; Pacheco FM; Zacharias TE; Litvak P; Sguigna P; Marder E; Kia K; Kooner K; Stüve O
J Neurol; 2016 Mar; 263(3):606-10. PubMed ID: 26914924
[TBL] [Abstract][Full Text] [Related]
13. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
Krasnov VS; Kolontareva YM
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Cree BA; Arnold DL; Fox RJ; Gold R; Vermersch P; Benedict RH; Bar-Or A; Piani-Meier D; Rouyrre N; Ritter S; Kilaru A; Karlsson G; Giovannoni G; Kappos L
Mult Scler; 2022 Sep; 28(10):1591-1605. PubMed ID: 35380078
[TBL] [Abstract][Full Text] [Related]
15. Siponimod in the treatment of multiple sclerosis.
Goodman AD; Anadani N; Gerwitz L
Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
[No Abstract] [Full Text] [Related]
16. Myelin Imaging in Human Brain Using a Short Repetition Time Adiabatic Inversion Recovery Prepared Ultrashort Echo Time (STAIR-UTE) MRI Sequence in Multiple Sclerosis.
Ma YJ; Jang H; Wei Z; Cai Z; Xue Y; Lee RR; Chang EY; Bydder GM; Corey-Bloom J; Du J
Radiology; 2020 Nov; 297(2):392-404. PubMed ID: 32779970
[TBL] [Abstract][Full Text] [Related]
17. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
[TBL] [Abstract][Full Text] [Related]
18. Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
Weier A; Enders M; Kirchner P; Ekici A; Bigaud M; Kapitza C; Wörl J; Kuerten S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430692
[TBL] [Abstract][Full Text] [Related]
19. Siponimod to treat secondary progressive multiple sclerosis.
Gajofatto A; Turatti M
Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
[TBL] [Abstract][Full Text] [Related]
20. Self-Assembled Fluorinated Nanoparticles as Sensitive and Biocompatible Theranostic Platforms for
Havlicek D; Panakkal VM; Voska L; Sedlacek O; Jirak D
Macromol Biosci; 2024 Jun; 24(6):e2300510. PubMed ID: 38217510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
